• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection.

作者信息

Hindilerden Fehmi, Yönal Hindilerden İpek, Diz Küçükkaya Reyhan

机构信息

Department of Hematology, University of Health Sciences, İstanbul Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey.

Division of Hematology, Department of Internal Medicine, İstanbul University İstanbul School of Medicine, İstanbul, Turkey.

出版信息

Balkan Med J. 2021 Mar;38(2):141-142. doi: 10.4274/balkanmedj.galenos.2020.2020.9.106.

DOI:10.4274/balkanmedj.galenos.2020.2020.9.106
PMID:33045824
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8909256/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c79/8909256/66a343b0ccc7/bmj-38-2-141-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c79/8909256/66a343b0ccc7/bmj-38-2-141-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c79/8909256/66a343b0ccc7/bmj-38-2-141-g01.jpg

相似文献

1
Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection.一名患有套细胞淋巴瘤且感染严重2019冠状病毒病的患者在停用依鲁替尼后病情迅速进展。
Balkan Med J. 2021 Mar;38(2):141-142. doi: 10.4274/balkanmedj.galenos.2020.2020.9.106.
2
Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy.依鲁替尼和维奈托克治疗后套细胞淋巴瘤中具有诊断挑战性的免疫表型转变
Pathology. 2021 Dec;53(7):926-929. doi: 10.1016/j.pathol.2021.01.013. Epub 2021 May 1.
3
Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients?伊布替尼对套细胞淋巴瘤患者感染新型冠状病毒肺炎的预后有影响吗？
Curr Res Transl Med. 2021 Jan;69(1):103273. doi: 10.1016/j.retram.2020.103273. Epub 2020 Nov 25.
4
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.在复发/难治性套细胞淋巴瘤中联合使用伊布替尼和维奈托克：3 期 SYMPATICO 研究的安全性预试验。
J Hematol Oncol. 2021 Oct 30;14(1):179. doi: 10.1186/s13045-021-01188-x.
5
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.伊布替尼治疗套细胞淋巴瘤首次复发：211 例英国真实世界研究结果分析。
Br J Haematol. 2021 Apr;193(2):290-298. doi: 10.1111/bjh.17363. Epub 2021 Feb 23.
6
CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.EZH1/2 双重抑制剂介导的 CDKN1C 抑制生长可克服套细胞淋巴瘤对依鲁替尼的耐药性。
Cancer Sci. 2021 Jun;112(6):2314-2324. doi: 10.1111/cas.14905. Epub 2021 May 1.
7
Successful Long-Term Ibrutinib Treatment in a Hemodialysis Patient With Leukemic Nonnodal Mantle Cell Lymphoma.伊布替尼对一名接受血液透析的白血病非结外型套细胞淋巴瘤患者的长期成功治疗
Clin Lymphoma Myeloma Leuk. 2021 Feb;21(2):e176-e178. doi: 10.1016/j.clml.2020.10.007. Epub 2020 Oct 9.
8
[Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib].[经鼻胃管给予伊布替尼成功治疗中枢神经系统复发的套细胞淋巴瘤]
Rinsho Ketsueki. 2020;61(10):1508-1510. doi: 10.11406/rinketsu.61.1508.
9
A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.Copanlisib联合依鲁替尼治疗复发/难治性套细胞淋巴瘤的1期试验。
Blood Adv. 2022 Sep 27;6(18):5262-5266. doi: 10.1182/bloodadvances.2021006555.
10
Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.转录编程驱动套细胞淋巴瘤对伊布替尼耐药的演变。
Cell Rep. 2021 Mar 16;34(11):108870. doi: 10.1016/j.celrep.2021.108870.

引用本文的文献

1
Impact of COVID-19 in patients with lymphoid malignancies.新型冠状病毒肺炎对淋巴系统恶性肿瘤患者的影响。
World J Virol. 2021 May 25;10(3):97-110. doi: 10.5501/wjv.v10.i3.97.

本文引用的文献

1
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.在重症 COVID-19 患者中抑制布鲁顿酪氨酸激酶。
Sci Immunol. 2020 Jun 5;5(48). doi: 10.1126/sciimmunol.abd0110.
2
Incidence of thrombotic complications in critically ill ICU patients with COVID-19.COVID-19 重症监护病房危重症患者的血栓并发症发生率。
Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10.
3
Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.布鲁顿酪氨酸激酶抑制剂治疗复发或难治性套细胞淋巴瘤的研究进展。
Curr Oncol. 2019 Apr;26(2):e233-e240. doi: 10.3747/co.26.4345. Epub 2019 Apr 1.
4
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion.伊布替尼用于套细胞淋巴瘤患者：是喜忧参半？证据与观点。
Ther Adv Hematol. 2015 Oct;6(5):242-52. doi: 10.1177/2040620715592569.